This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

HR-QoL and Sexuality in Mirena Inserted Contraception Users

This study has been completed.
Information provided by:
Bayer Identifier:
First received: July 9, 2007
Last updated: January 21, 2013
Last verified: January 2013
The purpose of this study is to evaluate the changes in the quality of life, as well as in the sexual activity, in women inserted with MIRENA, a hormonal contraceptive intra-uterine system, over the first 12 months of use. Patients switching from oral contraception to an intrauterine contraceptive device (here: MIRENA) will be observed in the first year post MIRENA insertion.

Condition Intervention Phase
Contraception Drug: Mirena Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Open Labelled, Uncontrolled, Phase IV Clinical Study to Evaluate the Health-related Quality of Life and Sexual Well-being in Young (18-35) Healthy Mirena Users Switching From OC, Over the First Year Post-insertion.

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Health-related QoL score [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Sexuality Index, treatment satisfaction, usual safety outcomes [ Time Frame: 1 year ]

Enrollment: 141
Study Start Date: November 2005
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Mirena
Mirena 52mg during 1 year


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy woman willing to, or having to switch from her OC to another contraceptive method

Exclusion Criteria:

- Any contraindication to Mirena insertion/use

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00498784

Bordeaux, Gironde, France, 33076
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Medical Affairs Therapeutic Area Head, Bayer Healthcare AG Identifier: NCT00498784     History of Changes
Other Study ID Numbers: 91458
2005-002955-42 ( EudraCT Number )
309663 ( Other Identifier: Company internal )
Study First Received: July 9, 2007
Last Updated: January 21, 2013

Keywords provided by Bayer:
Intra-uterine contraception
Intrauterine Devices

Additional relevant MeSH terms:
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral processed this record on June 23, 2017